Laidlaw lowered the firm’s price target on Beyond Air (XAIR) to $5 from $8 and keeps a Buy rating on the shares following the fiscal Q2 report. The firm says Beyond Air is at the early execution stage of LungFit PH commercialization by the new commercial team. It expects more significant sales starting in 2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.